Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ARAVIVE, INC (ARAV : NSDQ)

• Company Description    Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 74,328 shares Shares Outstanding: 28.83 (millions) Market Capitalization: $30.84 (millions) Beta: 2.57 52 Week High: $6.94 52 Week Low: $1.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -34.76% -28.56% 12 Week -50.69% -44.58% Year To Date -51.14% -40.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL River Oaks Tower 3730 Kirby Drive Suite 1200 - Houston,TX 77098 USA ph: 936-355-1910 fax: - lheagle@w2ogroup.com https://aravive.com

• General Corporate Information    Officers Gail McIntyre - President; Chief Executive Officer and Director Fredric N. Eshelman - Executive Chairman of the Board of Directors Leonard Scott Dove - Chief Operating Officer Vinay Shah - Chief Financial Officer Sigurd C. Kirk - Director Peer Information ARAVIVE, INC (CORR.) ARAVIVE, INC (RSPI) ARAVIVE, INC (CGXP) ARAVIVE, INC (BGEN) ARAVIVE, INC (GTBP) ARAVIVE, INC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03890D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 28.83 Most Recent Split Date: 10.00 (0.17:1) Beta: 2.57 Market Capitalization: $30.84 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.66 Price/Cash Flow: - Price / Sales: 3.73 EPS Growth vs. Year Ago Period: -40.91% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 326.56% vs. Previous Quarter: 10.86% ROE 03/31/22 - -88.49 12/31/21 - -68.29 09/30/21 - -51.44 ROA 03/31/22 - -58.22 12/31/21 - -49.39 09/30/21 - -38.16 Current Ratio 03/31/22 - 3.49 12/31/21 - 3.50 09/30/21 - 5.04 Quick Ratio 03/31/22 - 3.49 12/31/21 - 3.50 09/30/21 - 5.04 Operating Margin 03/31/22 - -533.99 12/31/21 - -526.08 09/30/21 - -249.06 Net Margin 03/31/22 - -533.99 12/31/21 - -526.08 09/30/21 - -249.06 Pre-Tax Margin 03/31/22 - -533.99 12/31/21 - -526.08 09/30/21 - -249.06 Book Value 03/31/22 - 1.61 12/31/21 - 2.01 09/30/21 - 2.59 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©